LUNG CANCER INTRODUCTION
|
|
- Sabina Golden
- 8 years ago
- Views:
Transcription
1 LUNG CANCER INTRODUCTION Lung cancer remains the leading cause of cancer death in the UK. Approximately 50% of those diagnosed present with stage IV disease. Significant advances in the management of lung cancer have occurred in the past decade. These changes have been systematically reviewed and incorporated into updated guidance from NICE (1) and SIGN (2). The National Lung Cancer Audit (NLCA) data continues to be published annually, allowing tracking of changes in patterns of care across the UK (3). Overall survival has increased in lung cancer in the past ten years with the vast majority of the gains occurring in disease stages I III. There has been very little, if any, improvement seen in outcomes for stage IV patients (4). Many publications have looked at access to radiotherapy treatments (5; 6). Although many of these do not distinguish between radical and palliative fractionations it appears that the proportion of lung cancer patients in the UK accessing radiotherapy remains lower than expected. The increased use of systemic therapy combined with the increasing availability and evidence base to support the use of SABR for medically inoperable patients implies a shift has occurred, with proportionately more patients accessing radical radiotherapy. Lung cancer staging has improved with routine use of CTPET and increasingly EBUS. Routine use of IV contrast in planning has improved mediastinal target delineation. Significant technological advances have occurred in the delivery of radiotherapy. For radical radiotherapy 4DCT planning is replacing 3DCRT as the standard of care. IMRT and VMAT are often being used for SABR techniques. Uptake of IMRT varies significantly across the country. Tumours in certain anatomical locations such as the paravertebral gutter have improved dosimetry with IMRT. Bulky tumours planned with IMRT can more often meet NTC than those planned conformally (7; 8). However, as with many tumour types, there is limited evidence of benefit beyond improved dosimetry. For this reason although IMRT is increasingly being adopted as the new paradigm for radical treatment it is not recommended for routine use by a number of bodies (2; 9). NON-SMALL CELL LUNG CANCER (NSCLC): CURATIVE THERAPY For patients with stage I and II lung cancer, anatomically based surgical resection remains the treatment of choice. There is an emerging body of literature to support ablative therapies in node negative patients of which SABR has the most mature evidence base. There are, as yet, no randomised studies but there are a number of multi-institutional prospective as well as retrospective series. Most concentrate on medically inoperable patients who are by definition less well than their surgical counterparts. Published outcomes both in terms of overall survival and disease free survival approach surgical series. 2 year survival has been reported as 70% (10) and 5 year survival 43% (11). For medically inoperable patients with node negative tumours less than 5cm and favourable anatomical position, SABR is the treatment of choice. Best outcomes occur when the tumour receives >100Gy BED. Treatment should be delivered with an interfraction interval of greater than 40 hours but less than 4 days (12). Page 1 of 8
2 Stage III NSCLC is an extremely heterogeneous group in terms of tumour size and extent of nodal involvement. Although trimodality therapy remains an option, there is no evidence of benefit over definitive chemoradiotherapy. Concurrent chemoradiotherapy has been demonstrated in meta-analyses to give superior outcomes when compared with sequential chemoradiotherapy (13; 14), or radiotherapy alone (14) but the optimum dose fractionation schedule has yet to be defined. Concurrent schedules have an increased incidence of grade 3 oesophageal toxicities. Following publication of the SOCCAR trial, 55Gy in 20# in 4 weeks delivered concurrently with cisplatin and vinorelbine remains the most commonly delivered concurrent schedule in the UK at present (15). Elderly patients with good performance status and few comorbidities derive as much benefit from concurrent therapy as their younger counterparts (16). There is no evidence of benefit for chemotherapy delivered either neoadjuvantly or adjuvantly to those receiving concurrent regimes. Dose escalation has been investigated in many studies. The recently published RTOG 0617 did not demonstrate a survival benefit in the escalated arm. This trial has received significant interest and review of individual data. The quality assurance of the radiotherapy may have been responsible for the lack of a positive outcome so it is likely that this issue will be revisited (17). For those unable to tolerate concurrent chemoradiotherapy, a sequential approach demonstrates survival benefit over radiotherapy alone. Again the optimum therapy schedule has yet to be defined. Patients unfit for systemic therapy should be treated with radiotherapy alone. Accelerated fractionation schedules seem to improve outcomes (18; 19) and can be safely combined with concurrent and neoadjuvant approaches (15; 20; 21). In the UK 55Gy in 20 fractions remains the most common radical fractionation (22). In the near future the UK will embark on a multiarm phase II trial comparing chemoradiotherapy delivered using novel fractionation regimens to determine the most useful schedule (ADSCaN). RECOMMENDATION Medically inoperable T1-3( 5cm) N0 SABR using (a) 54Gy/3# over 5 8 days (Grade C) (b) 55-60Gy/5# over days (Grade C) (c) 60Gy/8# over days (Grade C) Medically inoperable stage I and II CHART 54Gy in 36# over 12 consecutive days (Grade A) 55Gy in 20# over weeks (Grade B) STAGE III CONCURRENT: 55Gy in 20# with cisplatin and vinorelbine (Grade B) or 60 66Gy in 30-33# Page 2 of 8
3 with cisplatin and etoposide (Grade A) SEQUENTIAL: 55Gy in 20# (Grade B) or Gy in 30 33# (Grade B) or 54Gy in 36# over 12days (Grade B) RADIOTHERAPY ALONE: 54Gy in 36# over 12days (Grade A) or 55Gy in 20# (Grade B) or Gy in 30 33# (Grade B) NSCLC: PALLIATIVE RADIOTHERAPY Between 1989 and 1995, the MRC conducted a number of trials to determine the optimum radiotherapy schedule for palliation of intrathoracic symptoms from lung cancer. These trials were undertaken predominantly in the patients unexposed to chemotherapy. Current practice would see a significant proportion of patients receiving sequential chemoradiotherapy, with some of the stage III patients being managed with concurrent chemoradiotherapy thanks to IMRT techniques. A number of trials have been performed subsequently. Overall the trials demonstrate that short course radiotherapy can palliate intrathoracic symptoms as well as long course but for those with good PS higher doses confer a moderate survival advantage at the expense of extra toxicity (23). RECOMMENDATION For those with good PS 39Gy in 13# over 17 days with cord shielding or 36Gy in 12# over 16 days (Grade A) or 30Gy in 10# over 14 days (Grade A) or 20Gy in 5# over 5 days (Grade A) For those with poor PS 17Gy in 2# with cord shielding (Grade A) or SMALL CELL LUNG CANCER (SCLC) INTRODUCTION Small cell lung cancer (SCLC) is an aggressive disease that is systemic in nature from the outset. The incidence of SCLC is decreasing in the UK (currently 10 15% of all lung malignancies), probably due to reduced smoking burden. The TNM system has replaced VALG for staging SCLC. Overall survival in SCLC remains poor despite many aggressive approaches to therapy. Those who have good PS, few comorbidities and small volume disease have the best survival. The Page 3 of 8
4 evidence base now favours integration of chemotherapy and radiotherapy at all disease stages. CONCURRENT CHEMORADIOTHERAPY (STAGES I III) For patients with T1 4 and N0 3 SCLC there is clear evidence of benefit for concurrent chemoradiotherapy with radiotherapy starting no later than day 1 cycle 3 of chemotherapy. The optimal dose schedule is not yet determined, but an acceptable standard of care is 45Gy in 30 # treating twice daily (24). The UK led phase III trial CONVERT comparing the internationally accepted standard of 45Gy in 30# treating twice daily over three weeks with 66Gy in 33 daily fractions over six weeks will report in In addition a US Intergroup study is currently recruiting which compares three fractionation schedules (45Gy in 30# treating twice daily; 70Gy in 35 daily fractions and 61.2Gy over five weeks treating once daily until day 21 and twice daily thereafter). These trials should establish the accepted schedule against which future trials will be compared. One trial of early versus late concurrent thoracic radiotherapy used 40Gy in 15 daily fractions using a simple parallel opposed pair with cord shielding, which can be useful where OAR constraints cannot be otherwise met (25). SEQUENTIAL CHEMORADIOTHERAPY (STAGES I III) For those patients who, due to tumour size or comorbidities, cannot be treated with concurrent chemoradiotherapy, sequential chemoradiotherapy is the best alternative. There is no definitive evidence to indicate the optimal schedule in this patient group, although many use 40Gy in 15 daily fractions. RECOMMENDATION Concurrent chemoradiotherapy with cisplatin and etoposide should be delivered with either (a) 45Gy in 30 fractions over 3 weeks (Grade A) and (b) 40Gy once daily in 15 fractions over 3 weeks (Grade B) Sequential chemoradiotherapy 40Gy in 15 daily fractions should be delivered (Grade B) SCLC: PALLIATIVE THORACIC RADIOTHERAPY Commonly, in metastatic SCLC, palliative thoracic radiotherapy in the context of persistent and / or symptomatic thoracic disease following primary chemotherapy has often been delivered without a strong evidence base. A Page 4 of 8
5 recent EORTC trial randomised 498 patients with metastatic SCLC, who had not progressed during primary chemotherapy to PCI with or without thoracic radiotherapy with 30Gy in 10 daily fractions in addition. The trial did not meet its primary endpoint of improved OS at one year, but OS at 2 years was in favour of mediastinal consolidation (26). Further data analysis has confirmed the OS and DFS are limited to those with persistent intrathoracic disease (27) RECOMMENDATION: Those patients with metastatic SCLC who respond to primary chemotherapy should be considered for thoracic consolidation radiotherapy with 30Gy in 10 fractions (Grade A) PROPHYLACTIC CRANIAL IRRADIATION (PCI) (STAGES I III) Meta-analysis of patients with stages I III SCLC in complete or near complete thoracic remission following primary chemoradiotherapy have an increased OS and decreased incidence of intracerebral relapse when PCI is delivered (28; 29). 25Gy in 10 fractions over 14 days carries the same disease relapse rate but lower mortality when compared with 36Gy in 18 fractions over 24 days (29). RECOMMENDATION: For selected patients with SCLC, prophylactic cranial radiotherapy 25Gy in 10 daily fractions is recommended for those achieving good partial or complete response (Grade A) PROPHYLACTIC CRANIAL IRRADIATION (PCI) (STAGE IV) Patients with stage IV SCLC who had any response to primary chemotherapy were randomised to either PCI with one of five schedules (20 30Gy in 5 10 daily fractions) or no PCI. The treatment arm had an increased OS and reduced symptomatic incidence of brain metastases. 85% of patients were treated with either 30Gy in 10 fractions or 20Gy in 5 fractions. Two thirds received 20Gy in 5 fractions. Given that the 30Gy regimen has been superseded in early stage disease, most would now deliver 20Gy in 5 fractions. The trial excluded patients above 75 years of age (30). RECOMMENDATION: Selected patients with metastatic SCLC who respond to primary chemotherapy should be offered PCI with 20Gy in 5 fractions (Grade A). Page 5 of 8
6 MESOTHELIOMA INTRODUCTION Mesothelioma is a malignant disease of the pleura. The only identified and strongest aetiological factor is asbestos exposure. Incidence of the disease has increased worldwide since the turn of the century. In the UK incidence has plateaued over the past 4 years. Mesothelioma carries with it a poor prognosis. Interest in trimodality therapy has increased in recent years with little evidence of benefit. Another question which periodically emerges is the use of prophylactic irradiation of tracts of pleural interventions. This is thought to prevent painful chest wall recurrences developing. Two very small randomised studies have been reported, one demonstrating benefit, one not (31; 32). Currently in the UK two studies are addressing this issue. PIT randomises those with a visible scar following minor pleural interventions between 21Gy in 3 daily fractions using electrons or no treatment. It will close to recruitment in late The SMART trial, now closed to recruitment, randomised those with larger pleural interventions between immediate radiotherapy with 21Gy in 3 daily fractions and radiotherapy deferred until tract metastases occur. RECOMMENDATION: Routine prophylactic irradiation of tracts is not recommended (Grade B). REFERENCES 1. National Institute for Health and Clinical Excellence. Lung Cancer: diagnosis and treatment NICE 2011: 2. Scottish Intercollegiate Guidelines Network Guideline 137. Management of patients with lung cancer SIGN 2014: 3. National Lung Cancer Audit NLCA 2014: www National Cancer Intelligence Network. Survival by stage NCIN 2014: 5. Koning C C E et al. Mapping Use of Radiotherapy for Patients with Non-small Cell Lung Cancer in the Netherlands between 1997 and 2008 Clinical Oncology 24, (2011) 6. Delaney G P and Barton M Evidence-based Estimates of the Demand for Radiotherapy Clinical Oncology, Volume 27, Issue 2, (2015) 7. Harris et al A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncolo Biol Phys, 88: (2014) Page 6 of 8
7 8. Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C IASLC Advanced Radiation Technology Committee. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol Nov;9(11): Bezjak, A. et al. Intensity-modulated Radiotherapy in the Treatment of Lung Cancer Clinical Oncology, Volume 24, Issue 7, Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I nonsmall cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys Nov 1;90(3): Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys Dec 1;84(5): SABR UK Consortium. Stereotactic ablative radiotherapy (SABR): A resource. Version 5.0, January Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006; 17: O Rourke N, Roqué i FigulsM, Farré Bernadó N,Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD DOI: / CD pub Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. Eur J Cancer ;50(17): Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, et al. Updatedsurvival and outcomes for older adults with inoperable stage III non-small-cel lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol ;23: Bradley J D et al Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. The Lancet Oncology. 16 (2) (pp ), Saunders M, Dische S, Barrett A, et al. Continuous hyper-fractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial CHART Steering Committee. Lancet 1997,350: Pemberton LS et al Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome. Clin Oncol (R Coll Radiol). 21(3):161-7, 2009 Apr. 20. Hatton M et al Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial. Int J Radiat Oncol Biol Phys. 81(3):712-8, 2011 Nov 1 Page 7 of 8
8 21. Price A, Yellowlees A, Keerie C, Russell S, Faivre-Finn C, Gilligan D, Snee M, Skailes G, Hatton M, Erridge S, Mohammed N. Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable nonsmall cell lung cancer. Lung Cancer Sep;77(3): Royal College of Radiologists National Audit of Radical Radiotherapy in Lung Cancer Toy E, Macbeth F, Coles B, et al. Palliative thoracic radiotherapy for nonsmall-cell lung cancer: a systematic review. Am J Clin Oncol 2003, 26: Turessi AT, Kim K, Blum R, et al., Twice daily compared with once daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 1999, 340: Murray N; Coy P; Pater JL et al Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology February 1993 vol 11 no Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre- Finn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet Jan 3;385(9962): Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre- Finn C, Senan S. Which patients with extensive-stage small cell lung cancer (ES-SCLC) are most likely to benefit from routine thoracic radiotherapy (TRT) following chemotherapy? Lancet in press 28. Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341: Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu, T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC , RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol May;10(5): Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P,Collette L, Musat E, Senan S; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med Aug 16;357(7): 31. Boutin C; Rey F; Viallat JR Prevention of malignant seeding after invasive diagnostic procedures in patients with malignant pleural mesothelioma. A randomised trial of local radiotherapy Chest 1995 Sep; 108(3): O Rourke N; Garcia JC; Paul J; Lawless C; McMenemin R; Hill J A Randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma Radiother Oncol 2007 Jul;84(1): Epub 2007 Jun 22 Page 8 of 8
4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
More informationPulmonary function. Is patient potentially operable? Yes. tests 3. Yes. Pulmonary function. tests 3, if clinically indicated. Yes
INITIAL EVALUATION Pathology consistent with small cell lung cancer History and physical Chest X-ray Laboratory studies to include: hematological and full chemistry panels CT chest and upper abdomen Pet
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationTreatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
More informationStage IIIB disease includes patients with T4 tumors,
Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationTreatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
More informationManagement of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Abstract Introduction Management of stage III non small-cell lung cancer (NSCLC) is complex and requires careful work-up, staging,
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationCesare Gridelli 1, Francesca Casaluce 2, Assunta Sgambato 2, Fabio Monaco 3, Cesare Guida 4
Editorial Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that s the question Cesare Gridelli 1, Francesca
More informationREPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in
More informationthe standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationIs an evidence-based approach realistic in non-small cell lung cancer (NSCLC)?
Is an evidence-based approach realistic in non-small cell lung cancer (NSCLC)? Authors Key words P.A. Coucke, N. Barthelemy, L. Bosquee, J.P. van Meerbeeck NSCLC, sequential and concomitant chemo-radiotherapy,
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationHow To Improve Lung Cancer Survival With Radiation Therapy
Clinical Controversies: Proton Therapy for Thoracic Tumors Dirk De Ruysscher, MD, PhD,* and Joe Y. Chang, MD, PhD Photon and proton therapy techniques have both improved dramatically over the past decade.
More informationMoving towards novel treatments in mesothelioma. Paul Baas, The Netherlands Cancer Institute Rolf Stahel, University Clinic Zurich
Moving towards novel treatments in mesothelioma Paul Baas, The Netherlands Cancer Institute Rolf Stahel, University Clinic Zurich Malignant pleural mesothelioma (MPM) has proven to be quite resistant to
More informationSurvey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales
Eur Respir J 1997; 10: 1552 1558 DOI: 10.1183/09031936.97.10071552 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Survey on the treatment
More informationTreatment of Small Cell Lung Cancer
Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationHelical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc.
CLINICAL FEATURE Helical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc. The Challenge Lung cancer kills more people each year in the
More information5. Non small Cell Lung Cancer
5. Non small Cell Lung Cancer Introduction The cancer registry in Sweden shows a continuous increase of lung cancer cases from 867 in 1958 when the registry started to 2 846 in 2000. The Swedish cancer
More informationMalignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and
More informationTreatment of Stage III Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More information3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10
Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationMalignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationPlease see the LUCADA data manual v3.1.3, available in the downloads section
National Lung Cancer Audit Frequently Asked Questions What dataset should be used? Please see the LUCADA data manual v3.1.3, available in the downloads section What does LUCADA stand for? LUCADA stands
More informationEfficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer
[Chinese Journal of Cancer 27:10, 353-357; October 2008]; 2008 Sun Yat-Sen University Cancer Center Clinical Research Paper Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy
More informationClinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy for Non- Small-Cell Lung Cancer (Adult) April 2013 Reference: NHSCB/B01/P/a
Clinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy for Non- Small-Cell Lung Cancer (Adult) April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Stereotactic
More informationWho may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?
JBUON 2013; 18(2): 453-458 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Appropriateness Criteria Date of origin: 1996 Last review date: 2014 NONSURGICAL TREATMENT FOR LOCALLY ADVANCED NON SMALL-CELL LUNG CANCER: GOOD PERFORMANCE STATUS/DEFINITIVE
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationSpecial Article. Received 5 December 2014; revised 18 February 2015; accepted 25 February 2015. Practical Radiation Oncology (2015) 5, 141-148
Practical Radiation Oncology (2015) 5, 141-148 www.practicalradonc.org Special Article Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationNON-SMALL CELL LUNG CANCER STAGE III
NON-SMALL CELL LUNG CANCER STAGE III Effective Date: April, 2012 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently accepted
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationAltered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer
Evidence-based Series #7-12 Version 2 A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Altered Fractionation of Radical Radiation Therapy in the Management of
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationEVIDENCE TABLE. Study Objective. (Purpose of Study)
. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 997; (6):70-77.. Greene FL, Page DL, Fleming ID, et al, eds, for the American Joint Committee on Cancer. AJCC Cancer
More informationControversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
More informationTreatment of Small Cell Lung Cancer: American Society of Clinical Oncology. Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Table of Contents Data Supplement 1: Summary of included
More informationLung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
More informationSurgical therapy of. who should be operated
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationSmall-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
More informationUnderutilization of Radiotherapy for Lung Cancer in New South Wales, Australia
Underutilization of Radiotherapy for Lung Cancer in New South Wales, Australia Shalini K. Vinod, MBBS, MD, FRANZCR 1 ; Leonardo Simonella, BA, MPH 2 ; David Goldsbury, BSc, MPH 2 ; Geoff P. Delaney, MBBS,
More informationRadiotherapy for Non-Small Cell Lung Cancer. Standard Treatment Options Radiotherapy Planning
Radiotherapy for Non-Small Cell Lung Cancer I II Standard Treatment Options Radiotherapy Planning TNM Staging System Disease Staging - Management is based on disease stage - Stage I-II: early stage - Stage
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationJedi Wisdom for Lung Cancer Radiotherapy: May the Force Be With You
Jedi Wisdom for Lung Cancer Radiotherapy: May the Force Be With You SHAUN LOEWEN MD PhD FRCPC Assistant Professor, University of Manitoba Radiation Oncologist, CancerCare Manitoba Disclosure Relationship
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationStage 3 Lung Cancer - Know YourSurviving Conditions
Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Erich Kliewer Alain Demers Sri Navaratnam Coreen Hildebrand Grace Musto Report for AstraZeneca
More informationTreatment of stage III non-small cell lung cancer and limited-disease small-cell lung cancer
Treatment of stage III non-small cell lung cancer and limited-disease small-cell lung cancer ISBN/EAN 9789490122096 Cover photo: Monique Slagter-Verburg Layout: Karin van Rijnbach Print: Gildeprint Drukkerijen
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationB. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC
Lung Cancer B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC EPIDEMIOLOGY The estimated incidence of lung cancer in Canada for 2007 is 23,300 with 12,400 occurring in
More informationMalignant Mesothelioma: an Update
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationOutcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery
Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Hale B. Caglar, MD 1 ; Elizabeth H. Baldini, MD, MPH 1 ; Megan Othus, MS 2
More informationPII S0360-3016(99)00307-7 CLINICAL INVESTIGATION
PII S0360-3016(99)00307-7 Int. J. Radiation Oncology Biol. Phys., Vol. 45, No. 5, pp. 1151 1156, 1999 Copyright 1999 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/99/$ see front
More informationClinical Focus on Lung Cancer
Clinical Focus on Lung Cancer A snapshot of lung cancer for Ontario health care providers and managers Driving quality, accountability and innovation throughout Ontario s cancer system TABLE OF CONTENTS
More informationTreatment of Mesothelioma with Radiotherapy
41 Treatment of Mesothelioma with Radiotherapy Ryan P. Smith and Stephen M. Hahn General Principles of Radiation Therapy Radiation therapy is a therapeutic modality that uses ionizing radiation to treat
More informationNew Approaches for Small-Cell Lung Cancer: Local Treatments
The current management of limited-disease small-cell lung cancer is reviewed, and strategies to improve local control are discussed. Gary Ernest Smith. Sorting Old Bales. Oil on canvas, 18 24. Courtesy
More information2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)-
2015/16 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)- SECTION B PART 1 - SERVICE SPECIFICATION FOR LUNG CANCER Service specification
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationRadiation Therapy for Non-Small Cell Lung Cancer. Principles of Radiation Therapy for Non-small Cell Lung Cancer
Chapter 4 Radiation Therapy for Non-Small Cell Lung Cancer Join Y. Luh, MD, FACP and Charles R. Thomas, Jr., MD Introduction Radiation is a form of energy that has both beneficial and harmful effects on
More informationAmerican College of Radiology ACR Appropriateness Criteria RADIATION THERAPY FOR SMALL-CELL LUNG CANCER
Date of origin: 2012 American College of Radiology ACR Appropriateness Criteria RADIATION THERAPY FOR SMALL-CELL LUNG CANCER Expert Panel on Radiation Oncology Lung: Feng-Ming (Spring) Kong, MD, PhD, MPH
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
More informationThe Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model
The Evaluation of Cancer Control Interventions in Lung Cancer Using a Canadian Cancer Risk Management Model WK Evans, M Wolfson, WM Flanagan, J Shin, FF Liu JR Goffin, K Asakawa, N Mittmann, L Fairclough
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationEVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1
COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize
More informationRadiotherapy in Lung
Radiotherapy in Lung CancerAnatomy Oblique fissure in both lungs. Horizontal fissure in Right lung. Trachea bifurcates at the level of T5. Lymph nodes are divided into stations. Intrapulmonary, bronchopulmonary
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
ACR Appropriateness Criteria Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent Richard M. Gewanter, MD, Kenneth E. Rosenzweig, MD, Joe Yujiao Chang, MD, PhD,
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationa commitment in their practice to the roles and responsibilities of clinical oncologists X
CLINICAL ONCOLOGY BLUEPRINT OF ASSESSMENT SYSTEM Good Medical Practice areas of curriculum - ST5 (Intermediate) Standards GMP criterion Workplace based assessment By the end of the third year of training
More informationRadiotherapy in Lung Cancer. Dr. Vassilis Kouloulias. Radiotherapy in lung cancer. Dr. V. Kouloulias
Radiotherapy in Lung Cancer Dr. Vassilis Kouloulias Assistant Professor of Radiation Oncologist, 2 nd Dpt. Radiology, University of Athens, Greece. Key Words Small cell lung cancer (SCLC), Non-small cell
More informationRadioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
More information